Hyperthermic isolated limb perfusion for extremity soft tissue sarcomas: Systematic review of clinical efficacy and quality assessment of reported trials

Journal of Surgical Oncology

Volumn 106, Issue 8, 2012, Pages 921-928

  Trabulsi, N H ^a,b   Patakfalvi, L ^a   Nassif, M O ^a,b   Turcotte, R E ^a   Nichols, A ^c   Meguerditchian, A N ^a  

^a MCGILL UNIVERSITY   (Canada)

^b KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

^c URBAN INSTITUTE   (United States)

Author keywords

advanced disease; limb; regional chemotherapy

Indexed keywords

DOXORUBICIN; GAMMA INTERFERON; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

CANCER CHEMOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; EMBASE; EXTREMITY SOFT TISSUE SARCOMA; HUMAN; HYPERTHERMIC ISOLATED LIMB PERFUSION; LIMB SALVAGE; MEDLINE; METHODOLOGY; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SOFT TISSUE SARCOMA; SYSTEMATIC REVIEW; THERAPY; TOXICITY TESTING; TREATMENT RESPONSE;

CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CLINICAL TRIALS, PHASE II AS TOPIC; EXTREMITIES; HUMANS; HYPERTHERMIA, INDUCED; QUALITY ASSURANCE, HEALTH CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SARCOMA; TREATMENT OUTCOME;

EID: 84869412746     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23200     Document Type: Review

References (53)

1. Morrison BA,: Soft tissue sarcomas of the extremities. Proc (Bayl Univ Med Cent) 2003; 16: 285-290.
2. Hohenberger P, Wysocki WM,: Neoadjuvant treatment of locally advanced soft tissue sarcoma of the limbs: Which treatment to choose? Oncologist 2008; 13: 175-186.
3. Williard WC, Hajdu SI, Casper ES, et al.: Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 1992; 215: 269-275.
4. Sondak V,: Sarcomas of bone and soft tissue. Philadelphia: Lippincott Williams & Wilkins; 2000.
5. Clark MA, Thomas JM,: Amputation for soft-tissue sarcoma. Lancet Oncol 2003; 4: 335-342.
6. Wright EH, Gwilym S, Gibbons CL, et al.: Functional and oncological outcomes after limb-salvage surgery for primary sarcomas of the upper limb. J Plast Reconstr Aesthet Surg 2008; 61: 382-387.
7. Creech O, Jr., Krementz ET, Ryan RF, et al.: Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148: 616-632.
8. Eggermont AM, Schraffordt Koops H, Klausner JM, et al.: Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224: 756-764; discussion 764-755.
9. Eggermont AM, Brunstein F, Grunhagen D, et al.: Regional treatment of metastasis: Role of regional perfusion. State of the art isolated limb perfusion for limb salvage. Ann Oncol 2004; 15: iv107-iv112.
10. Grabellus F, Kraft C, Sheu SY, et al.: Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-o ± and melphalan: Histologically characterized improved margins correlate with absence of recurrences. Ann Surg Oncol 2009; 16: 676-686.
11. Benckhuijsen C, Kroon BB, van Geel AN, et al.: Regional perfusion treatment with melphalan for melanoma in a limb: An evaluation of drug kinetics. Eur J Surg Oncol 1988; 14: 157-163.
12. WorldHealthOrganization: WHO handbook for reporting results of cancer treatment. In "Geneva (Switzerland) World Health Organization Offset Publication No. 48; 1979.", 1979.
13. Wieberdink J, Benckhuysen C, Braat RP, et al.: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18: 905-910.
14. Johnson ML, Gordon HS, Petersen NJ, et al.: Effect of definition of mortality on hospital profiles. Med Care 2002; 40: 7-16.
15. Miller TE, Roche AM, Gan TJ,: Definitions and epidemiology. Curr Opin Crit Care 2009; 15: 314-319.
16. Chang SM, Reynolds SL, Butowski N, et al.: GNOSIS: Guidelines for neuro-oncology: Standards for investigational studies-reporting of phase 1 and phase 2 clinical trials. Neuro Oncol 2005; 7: 425-434.
17. Mariani L, Marubini E,: Content and quality of currently published phase II cancer trials. J Clin Oncol 2000; 18: 429-436.
18. Vickers AJ, Ballen V, Scher HI,: Setting the bar in phase II trials: The use of historical data for determining "go/no go" decision for definitive phase III testing. Clin Cancer Res 2007; 13: 972-976.
19. Higgins JP, Thompson SG,: Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
20. Gutman M, Inbar M, Lev-Shlush D, et al.: High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer 1997; 79: 1129-1137.
21. Gortzak E, Azzarelli A, Buesa J, et al.: A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 2001; 37: 1096-1103.
22. Mack LA, Crowe PJ, Jia LY, et al.: Preoperative chemoradiotherapy (modified Eilber protocol) provides maximum local control and minimal morbidity in patients with soft tissue sarcoma. Ann Surg Oncol 2005; 12: 646-653.
23. Temple CL, Ross DC, Magi E, et al.: Preoperative chemoradiation and flap reconstruction provide high local control and low wound complication rates for patients undergoing limb salvage surgery for upper extremity tumors. J Surg Oncol 2007; 95: 135-141.
24. Hegazy MA, Kotb SZ, Sakr H, et al.: Preoperative isolated limb infusion of Doxorubicin and external irradiation for limb-threatening soft tissue sarcomas. Ann Surg Oncol 2007; 14: 568-576.
25. Di Filippo F, Calabro AM, Cavallari A, et al.: The role of hyperthermic perfusion as a first step in the treatment of soft tissue sarcoma of the extremities. World J Surg 1988; 12: 332-339.
26. Van Ginkel RJ, Koops HS, De Vries EGE, et al.: Hyperthermic isolated limb perfusion with cisplatin in four patients with sarcomas of soft tissue and bone. Eur J Surg Oncol 1996; 22: 528-531.
27. Schwarzbach M, Lehnert T, Willeke F, et al.: Results of isolated hyperthermic extremity perfusion in soft tissue sarcomas within the scope of a multimodality treatment concept. [German]. Chirurg 1996; 67: 1237-1243.
28. Lienard D, Ewalenko P, Delmotte JJ, et al.: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52-60.
29. Van Horssen R, Ten Hagen TLM,: Eggermont AMM: TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist 2006; 11: 397-408.
30. Wray CJ, Benjamin RS, Hunt KK, et al.: Isolated limb perfusion for unresectable extremity sarcoma: Results of 2 single-institution phase 2 trials. Cancer 2011; 117: 3235-3241.
31. Grunhagen DJ, de Wilt JH, ten Hagen TL, et al.: Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nature clinical practice. Oncology 2006; 3: 94-103.
32. Moreno-Ramirez D, de la Cruz-Merino L, Ferrandiz L, et al.: Isolated limb perfusion for malignant melanoma: Systematic review on effectiveness and safety. Oncologist 2010; 15: 416-427.
33. Kraybill WG, Harris J, Spiro IJ, et al.: Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. Cancer 2010; 116: 4613-4621.
34. Aguiar S, Jr., Ferreira Fde O, Rossi BM, et al.: Neoadjuvant chemoradiation therapy for soft tissue sarcomas of the extremities. Clinics 2009; 64: 1059-1064.
35. Eilber FC, Rosen G, Eckardt J, et al.: Treatment-induced pathologic necrosis: A predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 2001; 19: 3203-3209.
36. Mack LA, Crowe PJ, Yang JL, et al.: Preoperative chemoradiotherapy (modified Eilber protocol) provides maximum local control and minimal morbidity in patients with soft tissue sarcoma. Ann Surg Oncol 2005; 12: 646-653.
37. Toulmonde M, Bellera C, Mathoulin-Pelissier S, et al.: Quality of randomized controlled trials reporting in the treatment of sarcomas. J Clin Oncol 2011; 29: 1204-1209.
38. Balasubramanian SP, Wiener M, Alshameeri Z, et al.: Standards of reporting of randomized controlled trials in general surgery: Can we do better? Ann Surg 2006; 244: 663-667.
39. Jacquier I, Boutron I, Moher D, et al.: The reporting of randomized clinical trials using a surgical intervention is in need of immediate improvement: A systematic review. Ann Surg 2006; 244: 677-683.
40. Solomon MJ, McLeod RS,: Clinical studies in surgical journals-Have we improved? Dis Colon Rectum 1993; 36: 43-48.
41. McCulloch P, Altman DG, Campbell WB, et al.: No surgical innovation without evaluation: The IDEAL recommendations. Lancet 2009; 374: 1105-1112.
42. Barkun JS, Aronson JK, Feldman LS, et al.: Evaluation and stages of surgical innovations. Lancet 2009; 374: 1089-1096.
43. Ergina PL, Cook JA, Blazeby JM, et al.: Challenges in evaluating surgical innovation. Lancet 2009; 374: 1097-1104.
44. Kusamura S, Baratti D, Younan R, et al.: The Delphi approach to Attain consensus in methodology of local regional therapy for peritoneal surface malignancy. J Surg Oncol 2008; 98: 217-219.
45. Younan R, Kusamura S, Baratti D, et al.: Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. J Surg Oncol 2008; 98: 253-257.
46. Bonvalot S, Laplanche A, Lejeune F, et al.: Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? Ann Oncol 2005: 1061-1068.
47. Di Filippo F, Rossi CR, Vaglini M, et al.: Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: results of a phase I study. J Immunother 1999; 22: 407-414.
48. Di Filippo F, Giacomini P, Rossi CR, et al.: Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO). In Vivo 2009; 23: 363-367.
49. Lejeune FJ, Pujol N, Lienard D, et al.: Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol 2000; 26: 669-678.
50. Lev-Chelouche D, Abu-Abeid S, Merimsky O, et al.: Isolated limb perfusion with high-dose tumor necrosis factor alpha and melphalan for Kaposi sarcoma. Archives of surgery 1999; 134: 177-180.
51. Rossi CR, Vecchiato A, Foletto M, et al.: Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer 1994; 73: 2140-2146.
52. Rossi CR, Foletto M, Mocellin S, et al.: Hyperthermic isolated perfusion with low-dose TNFalpha and doxorubicin in patients with locally advanced soft tissue limb sarcomas. J Chemother 2004; 16 (Suppl 5): 58-61.
53. Santinami M, Deraco M, Azzarelli A, et al.: Treatment of recurrent sarcoma of the extremities by isolated limb perfusion using tumor necrosis factor alpha and melphalan. Tumori 1996; 82: 579-584.